Compositions and methods for altering the biodistribution of biological agents

• US 5,849,727 A
• Filed: 06/28/1996
• Issued: 12/15/1998
• Est. Priority Date: 06/28/1996
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Nebraska
• Original Assignee: Board of Regents of the University of Nebraska
• Inventors: Iversen, Patrick L., Porter, Thomas R.
• Primary Examiner(s): Ketter, James
• Assistant Examiner(s): Yucel, Irem
• Application Number:
  US08/670,999
• Time in Patent Office: 900 Days
• Field of Search: 514/44, 514/156, 514/210, 514/226.2, 514/359, 514/396, 514/460, 514/471, 514/569, 514/577, 514/724, 514/776, 424/94.3
• US Class Current: 514/156
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 47/6925 the form being a microcapsule, nanocapsule, microbubble or nanobubble
• CPC Class Codes: A61K 49/223 Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/10 Antioedematous agents; Diuretics

Abstract

This invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic or bioactive agents. The methods and composition of the invention can be used with several therapeutic or bioactive agents and can achieve site-specific delivery of a therapeutic or biologically-active substance. This can allow for lower doses and for improved efficacy with drugs, particularly agents such as oligonucleotides which are plagued with problems in achieving therapeutic levels at targeted sites.

Claims

1. A method for delivering a biological agent to specific tissue sites comprising:

forming a solution of a plurality of albumin encapsulated, insoluble gas-filled microbubbles, said microbubbles associated to said biological agent;

administering said solution to an animal;

so that said protein directs the microbubble-associated agent to sites of bioprocessing of said protein and upon dissipation of the microbubble releases said agent;

wherein said biological agent is selected from the group consisting of naproxen, piroxicam, warfarin, furosemide, phenylbutazone, valproic acid, sulfisoxazole, ceftriaxone, and miconazole.

2. The method of claim 1 wherein said insoluble gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane, and perfluoropentane.

3. The method of claim 2 wherein said gas is perfluoropropane.

4. The method of claim 1 wherein said microbubbles are formed by the steps of:

mixing an aqueous solution comprising about 2% to about 10% by weight of human serum albumin diluted about two-fold to about eight-fold with 5% to 50% by weight of dextrose; and

exposing said solution to a sonication horn to create cavitation at particulate sites in said solution thereby generating stable microbubbles from about 0.1 to 10 microns in diameter.

5. The method of claim 4 wherein said dilution of albumin with dextrose is a three-fold dilution.

6. The method of claim 4 wherein said human serum albumin is a 5% by weight solution.

7. The method of claim 4 wherein said dextrose is a 5% by weight solution.

14. The method of claim 1 wherein said target site is the liver and the kidney of said animal.

8. A composition for delivery of a biological agent to a target site comprising:

an aqueous suspension comprising a plurality of albumin encapsulated insoluble gas-filled microbubbles and;

a biological agent selected from the group consisting of naproxen, piroxicam, warfarin, furosemide, phenylbutazone, valproic acid, sulfisoxazole, ceftriaxone, and miconazole associated to said albumin.

9. The composition of claim 8 wherein said gas is a perfluorocarbon gas.

10. The composition of claim 8 wherein said gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane, and perfluoropentane.

11. The composition of claim 10 wherein said gas is perfluorobutane.

12. The composition of claim 10 wherein said gas is perfluoropropane.

13. The composition of claim 8 wherein said microbubbles are 0.1 to 10 microns in diameter.